About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis

VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development of proprietary and innovative therapeutics to treat immune-inflammatory conditions. Shares of the biopharmaceutical company are rallying 31% through afternoon trading on Wednesday, April 19, 2023. Over the past three months, VYNE Therapeutics has seen average daily volume of 20,620 shares. However, volume of 33.52 million shares or dollar volume of around $137.1 million, has already exchanged hands through afternoon trading.

Shares of VYNE Therapeutics are climbing after the company disclosed promising preclinical results demonstrating the potential of its pan-BET inhibitor, VYN201, in treating idiopathic pulmonary fibrosis (IPF). In a widely recognized preclinical IPF model, VYN201 exhibited substantial anti-inflammatory and anti-fibrotic effects at 0.5 mg/ml and 1 mg/ml doses. VYN201 treatment significantly reduced lung fibrosis and hydroxyproline levels, while improving blood oxygen saturation and functional lung volume. These findings support the potential of VYN201 as a powerful, locally-administered therapy for various immuno-inflammatory conditions, validating the InhiBET™ BET inhibitor platform.

As a locally-administered “soft” drug, VYN201 targets multiple inflammatory cell signaling pathways with minimal systemic exposure. The encouraging data reveals its potential as a potent anti-inflammatory and anti-fibrotic agent, with applications across various immuno-inflammatory conditions. VYN201’s effectiveness in reducing lung fibrosis, hydroxyproline levels, and improving blood oxygen saturation and functional lung volume highlights its potential to transform the treatment landscape for IPF and related diseases.

“The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory and anti-fibrotic response,” said David Domzalski, President and Chief Executive Officer of VYNE. “These data in IPF support our thesis that VYN201 has potential utility as a locally-administered therapy across a variety of immuno-inflammatory indications and further underscores the potential value of our InhiBETTM BET inhibitor platform.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.